poziotinib

Poziotinib is an investigational small molecule tyrosine kinase inhibitor that irreversibly inhibits members of the human epidermal growth factor receptor (HER/ErbB) family, specifically EGFR (HER1 or ErbB1), HER2 (ErbB2), and HER4 (ErbB4), including their exon 20 insertion mutants. By binding to these receptors, poziotinib blocks downstream signaling pathways involved in cell proliferation and survival. Its small size and flexible structure allow it to overcome steric hindrance caused by exon 20 insertions, making it particularly effective against tumors with these mutations. Poziotinib has been primarily developed for the treatment of non-small cell lung cancer (NSCLC) harboring HER2 or EGFR exon 20 insertion mutations[1][5][6]. It has also been studied in breast cancer and other solid tumors[2].

Other names

1429757-68-5X4Z7U6JL1CX-4Z7U6JL1CX 4Z7U6JL1CPoziotinib HCl1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)-PIPERIDIN-1-YL)PROP-2-EN-1-ONE HYDROCHLORIDE2-Propen-1-one, 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)oxy)-1-piperidinyl)-, hydrochloride (1:1)